Yamaguchi O, Kasahara N, Soda H, Imai H, Naruse I, Yamaguchi H, Itai M, Taguchi K, Uchida M, Sunaga N, et al. Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib. Sci Rep. 2023. 13. 1
Kaira K, Imai H, Mouri A, Hashimoto K, Miura Y, Shiono A, Yamaguchi O, Kobayashi K, Kawasaki T, Yasuda M, et al. Clinicopathological impact of VEGFR2 and VEGF-C in patients with EGFR-major mutant NSCLC receiving osimertinib. Thorac Cancer. 2023. 14. 29. 2950-2961
Asao T, Shukuya T, Mimori T, Goto Y, Tanaka H, Takayama K, Tsubata Y, Tachihara M, Suzuki T, Kaira K, et al. Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101). Clin Lung Cancer. 2023. 24. 7
Imai H, Wasamoto S, Tsuda T, Nagai Y, Kishikawa T, Masubuchi K, Osaki T, Miura Y, Umeda Y, Ono A, et al. Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed. Thoracic Cancer. 2023. 14. 25. 2567-2578
Kuba K, Inoue H, Matsumura S, Enoki Y, Kogashiwa Y, Ebihara Y, Nakahira M, Yamazaki T, Yasuda M, Kaira K, et al. Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab. Kuba K, Inoue H, Matsumura S, Enoki Y, Kogashiwa Y, Ebihara Y, Nakahira M, Yamazaki T, Yasuda M, Kaira K, Kagamu H, Sugasawa M. Sci Rep. 2023. 13. 1. 22557
Neuroendocrine tumor of the breast with pulmonary metastasis 30 years after mastectomy
(32nd Congress of the European Society of Pathology and XXXIII International Congress of the International Academy of Pathology (Virchows Archiv) 2020)
